The DOI matches its Crossref record.
Pentoxifylline in treatment of sarcoidosis.
Abstract
The optimal therapy for sarcoidosis remains unclear. Most patients show a short-term response to corticosteroid therapy, but they have to face the risk of significant side effects. Because tumor necrosis factor alpha (TNF) plays a critical role in granuloma formation and sustenance as well as in the progression of sarcoidosis, we investigated pentoxifylline (POF), which exerts TNF-inhibitory activity, as a therapeutic agent in active pulmonary sarcoidosis. Twenty-three previously untreated patients with documented disease progression during the preceding 3 mo were treated with POF (25 mg/kg daily) and followed for 6 mo of therapy. Two patients were lost to follow-up, and three patients discontinued POF therapy because of gastrointestinal side effects; 18 patients were thus evaluated. Eleven patients improved, seven remained stable and, most importantly, none deteriorated. Lung function tests-DL(CO), Pa(O2) and Pa(O2)[exercise]-were significantly improved in the patient group as a whole and increased in a highly significant manner in those who improved. Three patients with corticosteroid-resistant disease progression were additionally treated with a combination of corticosteroids with POF. In all three patients the combination therapy resulted in an immediate complete decrease of disease activity, even after tapering prednisone to 7.5 mg daily or tapering off corticosteroids. These promising results suggest that POF may improve therapeutic regimens in pulmonary sarcoidosis either by sparing or replacing corticosteroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.ats4-99 · Cited by 1,902
Valeyre, D., Prasse, A., Nunes, H., Uzunhan, Y., Brillet, P.-Y., & Müller-Quernheim, J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60680-7 · Cited by 1,087
Interstitial lung disease guideline
Wells, A. U., Hirani, N., & on behalf of the BTS Interstitial Lung Disease Guideline Group, A. S. O. T. B. T. S. S. O. C. C. (2008) · Thorax · doi:10.1136/thx.2008.101691 · Cited by 866
Baughman, R. P., Lower, E. E., & du Bois, R. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12888-7 · Cited by 657
JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis ― Digest Version ―
Terasaki, F., Azuma, A., Anzai, T., Ishizaka, N., Ishida, Y., Isobe, M., Inomata, T., Ishibashi-Ueda, H., Eishi, Y., Kitakaze, M., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0508 · Cited by 479
Metadata
- Authors
- Zabel, P., Entzian, P., Dalhoff, K., & Schlaak, M.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-05
- Volume
- 155
- Issue
- 5
- Pages
- 1665-1669
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2170904073
- Cited by
- 220
- References
- 0
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pentoxifylline in treatment of sarcoidosis. https://app.cochat.ai/papers/10.1164/ajrccm.155.5.9154873
- The paper
- Zabel, P., Entzian, P., Dalhoff, K., & Schlaak, M. (1997). Pentoxifylline in treatment of sarcoidosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.155.5.9154873
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.